World News
Investing
Economy
Politics
Editor’s Pick

Acceleration of RAD204 Phase 1 dose escalation trial

by May 12, 2025

by May 12, 2025

Radiopharm Theranostics (RAD:AU) has announced Acceleration of RAD204 Phase 1 dose escalation trial

Download the PDF here.

This post appeared first on investingnews.com

0 comment

0

Facebook Twitter Pinterest Email

previous post

Multiple New Multi-Commodity Targets

next post

Anti-abortion provider measure in Trump’s ‘big, beautiful bill’ could spark House GOP rebellion

You may also like

Excellent Gold Intersections Verified at Kiimala Project

May 12, 2025

Multiple New Multi-Commodity Targets

May 12, 2025

Top 5 Canadian Mining Stocks This Week: Group...

May 11, 2025

Tech 5: OpenAI Restructures, Apple Pursues AI Search,...

May 11, 2025

Crypto Market Recap: Bitcoin Breaks US$100,000, Coinbase Makes...

May 11, 2025

Crypto Market Recap: Bitcoin Breaks US$100,000 as ETF...

May 10, 2025

Triumph Gold Updates Shareholders on Operations, Engages Market...

May 10, 2025

7 Copper ETFs and ETNs

May 10, 2025

Investing in Uranium ETFs: 9 Options for Uranium...

May 10, 2025

Buffett Hands Over Reins, What’s Next for Berkshire’s...

May 10, 2025

Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!

Your name
Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

About us
Contacts
Privacy Policy
Terms and Conditions
Email Whitelisting

Disclaimer: targetlinenews.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 targetlinenews.com | All Rights Reserved

World News
Investing
Economy
Politics
Editor’s Pick